Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities

SJ Tabrizi, C Estevez-Fraga… - The Lancet …, 2022 - thelancet.com
Huntington's disease is the most frequent autosomal dominant neurodegenerative disorder;
however, no disease-modifying interventions are available for patients with this disease. The …

Molecular mechanisms underlying nucleotide repeat expansion disorders

I Malik, CP Kelley, ET Wang, PK Todd - Nature reviews Molecular cell …, 2021 - nature.com
The human genome contains over one million short tandem repeats. Expansion of a subset
of these repeat tracts underlies over fifty human disorders, including common genetic …

The proteostasis network and its decline in ageing

MS Hipp, P Kasturi, FU Hartl - Nature reviews Molecular cell biology, 2019 - nature.com
Ageing is a major risk factor for the development of many diseases, prominently including
neurodegenerative disorders such as Alzheimer disease and Parkinson disease. A hallmark …

[HTML][HTML] Neurodegenerative disease: models, mechanisms, and a new hope

AD Gitler, P Dhillon, J Shorter - Disease models & …, 2017 - journals.biologists.com
Neurodegeneration is a feature of many debilitating, incurable diseases that are rapidly
rising in prevalence, such as Parkinson's disease. There is an urgent need to develop new …

[HTML][HTML] Huntingtin lowering strategies for disease modification in Huntington's disease

SJ Tabrizi, R Ghosh, BR Leavitt - Neuron, 2019 - cell.com
Huntington's disease is caused by an abnormally expanded CAG repeat expansion in the
HTT gene, which confers a predominant toxic gain of function in the mutant huntingtin …

[HTML][HTML] CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease

S Yang, R Chang, H Yang, T Zhao… - The Journal of …, 2017 - Am Soc Clin Investig
Huntington's disease is a neurodegenerative disorder caused by a polyglutamine repeat in
the Huntingtin gene (HTT). Although suppressing the expression of mutant HTT (mHTT) has …

[HTML][HTML] In situ architecture and cellular interactions of PolyQ inclusions

FJB Bäuerlein, I Saha, A Mishra, M Kalemanov… - Cell, 2017 - cell.com
Expression of many disease-related aggregation-prone proteins results in cytotoxicity and
the formation of large intracellular inclusion bodies. To gain insight into the role of inclusions …

Polyglutamine repeats in neurodegenerative diseases

AP Lieberman, VG Shakkottai… - Annual Review of …, 2019 - annualreviews.org
Among the age-dependent protein aggregation disorders, nine neurodegenerative diseases
are caused by expansions of CAG repeats encoding polyglutamine (polyQ) tracts. We …

Proteostasis impairment in protein-misfolding and-aggregation diseases

MS Hipp, SH Park, FU Hartl - Trends in cell biology, 2014 - cell.com
Cells possess an extensive network of components to safeguard proteome integrity and
maintain protein homeostasis (proteostasis). When this proteostasis network (PN) declines …

Systemic exosomal siRNA delivery reduced alpha‐synuclein aggregates in brains of transgenic mice

JM Cooper, PBO Wiklander, JZ Nordin… - Movement …, 2014 - Wiley Online Library
ABSTRACT Alpha‐synuclein (α‐Syn) aggregates are the main component of Lewy bodies,
which are the characteristic pathological feature in Parkinson's disease (PD) brain. Evidence …